BC‐11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS‐CoV‐2 host cell entry
Open Access
- 31 October 2022
- journal article
- research article
- Published by Wiley in Archiv der Pharmazie
- Vol. 356 (1) , e2200371
Abstract
Host cell entry of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is facilitated via priming of its spike glycoprotein by the human transmembrane protease serine 2 (TMPRSS2). Although camostat and nafamostat are two highly potent covalent TMPRSS2 inhibitors, they nevertheless did not hold promise in COVID‐19 clinical trials, presumably due to their short plasma half‐lives. Herein, we report an integrative chemogenomics approach based on computational modeling and in vitro enzymatic assays, for repurposing serine‐targeted covalent inhibitors. This led to the identification of BC‐11 as a covalent TMPRSS2 inhibitor displaying a unique selectivity profile for serine proteases, ascribable to its boronic acid warhead. BC‐11 showed modest inhibition of SARS‐CoV‐2 (omicron variant) spike pseudotyped particles in a cell‐based entry assay, and a combination of BC‐11 and AHN 1‐055 (a spike glycoprotein inhibitor) demonstrated better viral entry inhibition than either compound alone. Given its low molecular weight and good activity against TMPRSS2, BC‐11 qualifies as a good starting point for further structural optimizations.Keywords
Funding Information
- Deutscher Akademischer Austauschdienst (91653768)
- Deutsche Forschungsgemeinschaft (278002225 (RTG 2002))
This publication has 29 references indexed in Scilit:
- Current computational methods for predicting protein interactions of natural productsComputational and Structural Biotechnology Journal, 2019
- Structure-Based Virtual Screening Approach for Discovery of Covalently Bound LigandsJournal of Chemical Information and Modeling, 2014
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichmentsJournal of Computer-Aided Molecular Design, 2013
- Type II Transmembrane Serine Protease (TTSP) deregulation in cancerFrontiers in Bioscience-Landmark, 2011
- Phenotypic Analysis of Mice Lacking the Tmprss2-Encoded ProteaseMolecular and Cellular Biology, 2006
- Cathepsin L Is Involved in Proteolytic Processing of the Hendra Virus Fusion ProteinJournal of Virology, 2005
- [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].2000
- The Protein Data BankNucleic Acids Research, 2000
- Crysteine Proteases such as papain are not inhibited by substrate analogue peptidyl boronic acidsBioorganic & Medicinal Chemistry, 1997
- Metabolic fate of14C-camostat mesylate in man, rat and dog after intravenous administrationXenobiotica, 1994